A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes (NCT06924320)

🧪 Interventions in This Study

• MET233 and MET097 (DRUG)
• MET097 (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Adult males or females aged 18 to 75 years (inclusive) at the time of screening.
2. BMI ≥27.0 kg/m2 and ≤38.0 kg/m2 (inclusive) at Screening for Parts A, B, and C, and ≥30.0 kg/m2 and ≤45.0 kg/m2 (inclusive) at Screening for Parts D and E. Have a BMI ≥27.0 kg/m2 and ≤45.0 kg/m2 (inclusive) at Screening for Parts G.
3. Participants must be in generally stable health, as determined by the investigator based on medical history, physical examination (including vital signs), laboratory evaluations, and electrocardiogram (ECG).
4. Participants must have no clinically significant diseases or clinically significant findings on the physical examination (including vital signs), laboratory evaluations, and electrocardiogram (ECG).
5. Participants in Parts C must not have clinically significant diseases except type 2 diabetes mellitus (T2DM), sleep apnea, well-controlled hypertension, and/or dyslipidemia.
6. Participants in Parts E and G must not have any clinically significant diseases except hypertension, dyslipidemia, and/or a clinical diagnosis of sleep apnea.
7. Willing and able to comply with all scheduled study visits, procedures, and required assessments.
8. Women of childbearing potential must be willing to comply with protocol-specified contraceptive requirements and must not plan to become pregnant during the study.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

• Altasciences Clinical Los Angeles, Inc. — Cypress, California

📞 Contact the Study Coordinator

Phone: (800) 718-1021

Email: ClinicalTrials.gov_Inquiries@pfizer.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Obesity and Obesity-related Medical Conditions

• Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD) — Columbia, Missouri
• "F!reF!ghterF!t": Lifestyle Coaching Interventions for Obese Firefighters (FireFit) — Sommerville, Massachusetts
• 2024 Tirzepatide-Bariatric Surgery — Lexington, Kentucky
• Transition to Ambulatory Bariatric Surgery (TABS) Trial — Nashville, Tennessee
• Egg Intake, Metabolic Outcomes and Choline Levels — Québec, Quebec
• Bariatric Surgery vs. Semaglutide vs. Tirzepatide — Cleveland, Ohio

Explore by condition: All Obesity and Obesity-related Medical Conditions clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.